Loading
Life sciences · Journal article
Human Vaccines & Immunotherapeutics · September 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Respiratory syncytial virus (RSV), a common virus causing acute respiratory illness (ARI), can lead to severe disease among adults aged ≥50 y. We assessed healthcare resource utilization (HRU) and costs among United States (US) adults aged ≥50 y after hospitalization with RSV-ARI. Using 2015-2023 US claims data from the Optum® Clinformatics® Data Mart, three cohorts of patients aged ≥50 y were identified: patients with ≥1 RSV-ARI episode involving hospitalization (RSV-ARI cohort), patients with ≥1 influenza-ARI episode involving hospitalization (influenza-ARI cohort), and patients without recent ARI (control cohort). HRU and costs per-patient-per-month (PPPM) were assessed at 30 d, 3 months, and 1 y post-index. Adjusted regression models compared outcomes across cohorts. Overall, 14,759 patients were included in the RSV-ARI cohort, 77,468 in the influenza-ARI cohort, and 73,795 in the control cohort. The RSV-ARI cohort had significantly higher HRU vs. controls within 1 y post-index; adjusted incidence rate ratios (95% confidence interval) 30 d through 1 y post-index ranged from 81.07 (75.85, 86.65) to 11.56 (11.20, 11.93) for inpatient stays, 5.93 (5.58, 6.30) to 2.19 (2.09, 2.29) for emergency department visits, and 1.99 (1.95, 2.04) to 1.78 (1.75, 1.81) for outpatient visits. Adjusted total costs PPPM were higher for the RSV-ARI cohort vs. controls post-index (difference at 30 d: $37,025 [$36,345, $37,704]; 1 y: $6,699 [$6,476, $6,922]). HRU and costs among patients aged ≥50 y with RSV-ARI were higher vs. controls and generally similar between the RSV-ARI and influenza-ARI cohorts, demonstrating economic burden of severe RSV disease and the importance of RSV prevention.